La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DURECT Croissance future

Future contrôle des critères 2/6

DURECT devrait augmenter ses bénéfices et ses revenus de 33.3% et de 56.3% par an respectivement, tandis que le BPA devrait croître de croître de 31.2% par an.

Informations clés

33.3%

Taux de croissance des bénéfices

31.2%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	56.3%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	14 Aug 2024

Mises à jour récentes de la croissance future

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:DRRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	23	-38	N/A	N/A	1
12/31/2025	9	-41	N/A	N/A	1
12/31/2024	8	-27	N/A	N/A	3
6/30/2024	8	-16	-26	-26	N/A
3/31/2024	8	-23	-32	-32	N/A
12/31/2023	9	-28	-34	-34	N/A
9/30/2023	9	-37	-35	-34	N/A
6/30/2023	19	-36	-29	-29	N/A
3/31/2023	19	-36	-30	-30	N/A
12/31/2022	19	-35	-26	-26	N/A
9/30/2022	23	-32	-29	-29	N/A
6/30/2022	13	-39	-34	-34	N/A
3/31/2022	14	-37	-32	-32	N/A
12/31/2021	14	-36	-38	-37	N/A
9/30/2021	9	-38	-35	-35	N/A
6/30/2021	9	-37	-36	-36	N/A
3/31/2021	31	-14	-37	-37	N/A
12/31/2020	30	-14	-39	-39	N/A
9/30/2020	34	-11	-27	-26	N/A
6/30/2020	43	-3	1	1	N/A
3/31/2020	23	-24	4	4	N/A
12/31/2019	25	-21	11	11	N/A
9/30/2019	23	-24	1	1	N/A
6/30/2019	20	-24	-19	-19	N/A
3/31/2019	19	-24	-19	-19	N/A
12/31/2018	15	-25	-20	-20	N/A
9/30/2018	34	-10	-21	-21	N/A
6/30/2018	35	-1	-17	-17	N/A
3/31/2018	36	-4	N/A	1	N/A
12/31/2017	37	-4	N/A	-1	N/A
9/30/2017	21	-21	N/A	-1	N/A
6/30/2017	16	-36	N/A	-10	N/A
3/31/2017	15	-35	N/A	-30	N/A
12/31/2016	14	-35	N/A	-27	N/A
9/30/2016	16	-32	N/A	-26	N/A
6/30/2016	17	-29	N/A	-25	N/A
3/31/2016	18	-26	N/A	-22	N/A
12/31/2015	19	-23	N/A	-21	N/A
9/30/2015	18	-23	N/A	-17	N/A
6/30/2015	18	-23	N/A	-17	N/A
3/31/2015	18	-23	N/A	-17	N/A
12/31/2014	19	-22	N/A	-15	N/A
9/30/2014	19	-21	N/A	-15	N/A
6/30/2014	18	-20	N/A	-15	N/A
3/31/2014	17	-20	N/A	-15	N/A
12/31/2013	15	-21	N/A	-15	N/A
9/30/2013	14	-22	N/A	-15	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: DRRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: DRRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: DRRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DRRX ( 56.3% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DRRX ( 56.3% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de DRRX devrait être élevé dans 3 ans

DURECT Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target decreased to US$5.33

Consensus revenue estimates fall by 16%

No longer forecast to breakeven

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Forecast to breakeven in 2024

Recent updates

Consensus revenue estimates decrease by 21%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

DURECT Corporation to Report Q2, 2024 Results on Aug 13, 2024

DURECT Corporation, Annual General Meeting, Sep 25, 2024

DURECT Corporation to Report Q1, 2024 Results on May 13, 2024

DURECT Corporation to Report Q4, 2023 Results on Mar 27, 2024

DURECT Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

DURECT Corporation to Report Q3, 2023 Results on Nov 13, 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q2, 2023 Results on Aug 09, 2023

DURECT Corporation Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q3, 2022 Results on Nov 02, 2022

DURECT Corporation Announces Enrollment of More Than 200 of Planned 300 Patients in is Phase 2b AHFIRM Trial

Innocoll Pharmaceuticals Limited and DURECT Corporation Announce U.S. Launch of POSIMIR

DURECT Corporation Receives Approval from the Listing Qualifications Department of Nasdaq for an Additional 180-Day Grace Period, or Until February 6, 2023

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Price target decreased to US$5.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

DURECT Corporation to Report Q2, 2022 Results on Aug 04, 2022

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Durect names ex-RBC Capital Markets executive as CFO

High number of new directors

Is DURECT (NASDAQ:DRRX) A Risky Investment?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

DURECT Corporation, Annual General Meeting, Jun 15, 2022

Independent Director recently bought US$118k worth of stock

Consensus revenue estimates fall by 16%

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

No longer forecast to breakeven

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

DURECT Corporation Announces Resignation of Michael Arenberg as Chief Financial Officer, Effective March 17, 2022

Durect Corporation Doses First European Patient in Phase 2B Ahfirm Study of Larsucosterol(Dur-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation to Report Q4, 2021 Results on Mar 07, 2022

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

High number of new directors

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 3Q 2020)

Price target decreased to US$6.50

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.073 profit in 2Q 2020)

Price target increased to US$7.25

Forecast to breakeven in 2024

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and in Hepatic Impairment At Upcoming International Liver Conference 2021

Durect (DRRX) Investor Presentation - Slideshow

Durect EPS misses by $0.01, misses on revenue

Durect Corporation Announces Publication of Dur-928'S Mechanism of Action

DURECT Corporation to Report Q4, 2020 Results on Mar 04, 2021

DURECT prices ~$43M stock offering

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

DURECT surges after FDA approval for Posimir

DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

DURECT Corporation Announces Board Changes

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

DURECT Corporation Announces Dur-928 Granted Fda Fast Track Designation for Treatment of Alcoholic Hepatitis

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT (DRRX) Investor Presentation - Slideshow

DURECT Corporation to Report Q3, 2020 Results on Nov 02, 2020

DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1B Clinical Trial of Dur-928 in Nash Patients At the Liver Meeting Digital Experience 2020

DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

Durect Corporation Announces the Study Design for the Phase 2B Ahfirm Clinical Trial of DUR-928 in Severe Alcoholic Hepatitis (AH) Patients

Prévisions de croissance des bénéfices et des revenus